SLC5A2 and kidney disorder: The next part of this review will present various proposed mechanisms of SGLT2 inhibitors in the setting of heart and kidney diseases, first considering proposed mechanism by which these drugs benefit human patients and then discussing whether these benefits could be extrapolated to veterinary patients.